Immusoft Corporation, based in Seattle, is a pioneering cell therapy company focused on developing a novel approach to sustained delivery of protein therapeutics using the body's own cells. The company operates in the biotechnology and healthcare market, primarily serving patients with chronic diseases that require long-term treatment solutions. Immusoft's core technology, known as Immune System Programming (ISP), involves collecting a type of immune cell called B cells, programming them to produce specific therapeutic proteins, and then reintroducing these cells into the patient's body. These programmed B cells transform into plasma cells, which act as biofactories to produce and secrete therapeutic proteins continuously over extended periods. This innovative approach aims to provide a more effective and sustained treatment option compared to traditional therapies. Immusoft generates revenue through partnerships, licensing agreements, and potentially future commercialization of its proprietary therapies. The company targets a niche market with high unmet medical needs, positioning itself as a leader in the cell therapy space.

Keywords: cell therapy, B cells, protein therapeutics, chronic diseases, biofactory, plasma cells, immune system programming, biotechnology, healthcare, sustained delivery.